Law360, New York (December 30, 2008) -- The U.S. Federal Trade Commission has allowed King Pharmaceuticals Inc. to complete its approximately $1.6 billion acquisition of rival Alpharma Inc., but it forced the sale of Alpharma’s long-acting opioid analgesic drug, Kadian, to alleviate competition concerns.
The pharmaceutical was sold to generic-drug maker Actavis, which the FTC said should allow competition between Kadian and King’s long-acting opioid, Avinza. That competition would have been lost as a...
